A. Rheum, M. C. Walsh, Y. S. Choi, Y. Wittrant, S. Kwantat et al., Biology of the RANKL?RANK?OPG system in immunity, bone, and beyond The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, CrossRef PubMed Front. Immunol. Cytokine Growth Factor Rev, vol.70, issue.15, pp.104-108, 2004.

C. Pubmed-22-wittrant, Y. Théoleyre, S. Chipoy, C. Padrines, M. Blanchard et al., OPG: new therapeutic targets in bone tumours and associated osteolysis RANKL, a necessary chance for clinical application to osteoporosis and cancer, Biochim. Biophys. Acta, vol.1704, pp.49-57, 2004.

J. Li, Q. Yin, and H. Wu, Structural Basis of Signal Transduction in the TNF Receptor Superfamily, Adv. Immunol, vol.119, pp.135-153, 2013.
DOI : 10.1016/B978-0-12-407707-2.00005-9

D. M. Anderson, E. Maraskovsky, W. L. Billingsley, W. C. Dougall, M. E. Tometsko et al., A homologue of the TNF receptor and its ligand enhance T cell growth and dendritic cell function TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a New TNF family member predominantly expressed in T cells, is a dendritic cell specific survival factor, Nature J. Exp. Med, vol.390, issue.186, pp.175-179, 1997.

C. Pubmed-27-lacey, D. L. Timms, E. Tan, H. L. Kelley, M. J. Dunstan et al., Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation, Cell, vol.93, issue.2, pp.165-176, 1998.
DOI : 10.1016/S0092-8674(00)81569-X

C. Pubmed-28-kong, Y. Y. Boyle, W. J. Penninger, J. M. Kodaira, K. Mizuno et al., Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development, PubMed 30 Yasuda, Proc. Natl. Acad. Sci. U.S.A. 95, 3597?3602 CrossRef PubMed 31 Ikeda, pp.188-193, 1998.
DOI : 10.1126/science.177.4051.793

A. Hikita, I. Yana, H. Wakeyama, M. Nakamura, Y. Kadono et al., Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand Proteases and bone remodelling, CrossRef PubMed 33, pp.36846-36855, 2006.

V. Zhou, H. Horwood, N. J. Thomas, R. J. Hards, D. K. Quinn et al., Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis, Bone J. Biol. Chem, vol.25, issue.276, pp.525-534, 1999.

C. Pubmed-37-matsuzaki, K. Udagawa, N. Takahashi, N. Yamaguchi, K. Yasuda et al., Osteoclast Differentiation Factor (ODF) Induces Osteoclast-like Cell Formation in Human Peripheral Blood Mononuclear Cell Cultures, Biochemical and Biophysical Research Communications, vol.246, issue.1, pp.199-204, 1998.
DOI : 10.1006/bbrc.1998.8586

C. Pubmed-38-quinn, J. M. Elliott, J. Gillespie, M. T. Martin, T. J. Xiong et al., A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro Osteocytes not osteoblasts or lining cells are the main source of the RANKL required for osteoclast formation in remodeling bone Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand, Endocrinology PLoS One Proc. Natl. Acad. Sci. U.S.A. Nature, vol.139, issue.402, pp.4424-4427, 1998.

C. Pubmed-42-takayanagi, H. Wong, B. R. Josien, R. Lee, S. Y. Vologodskaia et al., The TRAF family of signal transducers mediates NF-kappaB Activation by the TRANCE receptor Self-assembled RANK induces osteoclastogenesis ligand-independently Novel RANK antagonists for the treatment of bone resorptive disease: theoretical predictions and experimental validation, Nat. Rev. Immunol. J. Biol. Chem. J. Bone Miner. Res. J. Bone Miner. Res, vol.7, issue.29, pp.292-304, 1998.

F. Arai, T. Miyamoto, O. Ohneda, T. Inada, T. Sudo et al., Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor ??b (Rank) Receptors, The Journal of Experimental Medicine, vol.21, issue.12, pp.1741-1754, 1999.
DOI : 10.1084/jem.177.1.237

C. Pubmed, .. Higashio, and K. , RANK is essential signalling receptor for osteoclast differentiation factor in osteoclastogenesis, Biochem. Biophys. Res. Commun, vol.253, pp.396-400, 1998.

J. Li, I. Sarosi, X. Q. Yan, S. Morony, C. Capparelli et al., RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism, Proc. Natl. Acad. Sci. U.S.A. 97, pp.1566-1571, 2000.
DOI : 10.1038/360741a0

W. C. Dougall, M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel et al., RANK is essential for osteoclast and lymph node development, CrossRef PubMed 49, pp.2412-2424, 1999.
DOI : 10.1101/gad.13.18.2412

URL : http://genesdev.cshlp.org/content/13/18/2412.full.pdf

M. Lamoureux, F. Duplomb, L. Rédini, F. Heymann, D. D. Perrone et al., RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases Expression pattern of receptor activator of NFkB (RANK) in a series of primary solid tumors and related metastases, CrossRef PubMed Cell. Mol. Life Sci. J. Cell Physiol, vol.50, issue.226, pp.2334-2350, 2007.

C. Pubmed-52-santini, D. Schiavon, G. Vincenzi, B. Gaeta, L. Pantano et al., Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer, PLoS One Clin. Cancer Res. J. Surg. Oncol, vol.6, issue.110, pp.162-165, 2005.

C. Pubmed-55-pfitzner, B. M. Branstetter, D. Loibl, S. Denkert, C. Lederer et al., RANK expression as a prognostic and predictive marker in breast cancer, Breast Cancer Research and Treatment, vol.130, issue.2, pp.307-315, 2014.
DOI : 10.1007/s10549-011-1715-8

C. Pubmed-56-jones, D. H. Nakashima, T. Sanchez, O. H. Kozieradzki, I. Komarova et al., Regulation of cancer cell migration and bone metastasis by RANKL, Nature, vol.17, issue.Suppl., pp.692-696, 2006.
DOI : 10.1023/A:1006689719505

C. Pubmed-57-owen, S. Ye, L. Sanders, A. J. Mason, M. D. Jiang et al., Expression profile of receptor activator of nuclear-?B (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer, Anticancer Res, vol.33, pp.199-206, 2013.

C. Van-poznak, S. S. Cross, M. Saggese, C. Hudis, K. S. Panageas et al., Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor ??B ligand (RANKL) in human breast tumours, Journal of Clinical Pathology, vol.59, issue.1, pp.56-63, 2006.
DOI : 10.1136/jcp.2005.026534

J. Azim, H. A. Peccatori, F. A. Brohée, S. Branstetter, D. Loi et al., RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy, Breast Cancer Research, vol.13, issue.1, p.24, 2015.
DOI : 10.1586/era.12.177

URL : https://breast-cancer-research.biomedcentral.com/track/pdf/10.1186/s13058-015-0538-7?site=breast-cancer-research.biomedcentral.com

C. Pubmed-60-hu, H. Wang, J. Gupta, A. Shidfar, A. Branstetter et al., RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase, Breast Cancer Res. Treat, vol.146, pp.515-523, 2014.

C. Pubmed-61-shang, W. Q. Li, H. Liu, L. B. Chang, K. K. Yu et al., RANKL/RANK interaction promotes the growth of cervical cancer cells by strengthening the dialogue between cervical cancer cells and regulation of IL-8 secretion Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis RANK rs1805034 T>C polymorphism is associated with susceptibility of esophageal cancer in a Chinese population RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone, Oncol. Rep. J. Cell Biochem. CrossRef PubMed Am. J. Pathol. CrossRef PubMed PLoS One J. Bone Miner. Res, vol.34, issue.21, pp.3007-3016, 2003.

C. Pubmed-66-branstetter, D. G. Nelson, S. D. Manivel, J. C. Blay, J. Y. Chawla et al., Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone, Clinical Cancer Research, vol.18, issue.16, pp.4415-4424, 2012.
DOI : 10.1158/1078-0432.CCR-12-0578

F. N. Duan, M. Liu, L. Z. Wang, Z. C. Shi, J. Y. Yang et al., RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-?B-mediated epithelial?mesenchymal transition, PLoS One, vol.9, pp.108507-68, 2014.

A. Sasaki, K. Ishikawa, N. Haraguchi, H. Inoue, T. Ishio et al., Receptor Activator of Nuclear Factor-??B Ligand (RANKL) Expression in Hepatocellular Carcinoma With Bone Metastasis, CrossRef PubMed 69 Peng, Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells, pp.1191-1199, 2001.
DOI : 10.1016/S0002-9440(10)64942-5

C. Pubmed-72-barcala, V. Ruybal, P. Garcia-rivello, H. Waldner, C. Ascione et al., RANKL expression in a case of follicular lymphoma, European Journal of Haematology, vol.98, issue.12, pp.417-419, 2003.
DOI : 10.1034/j.1600-0609.2003.00067.x

C. Pubmed and .. , This is an open access article, Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY)

M. Eickelmann, D. Metze, T. A. Luger, S. Beissert, K. S. Loser et al., RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma, J. Invest. Dermatol. CrossRef PubMed Br. J. Haematol, vol.131, issue.117, pp.944-955, 2002.

A. N. Farrugia, G. J. Atkins, L. B. To, B. Pan, N. Horvath et al., Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo, CrossRef PubMed 76, pp.5438-5445, 2003.

D. Granchi, I. Amato, L. Battistelli, S. Avnet, S. Capaccioli et al., In vitro blockade of receptor activator of nuclear factor-?B ligand prevents osteoclastogenesis induced by neuroblastoma cells, International Journal of Cancer, vol.33, issue.6, pp.829-838, 2004.
DOI : 10.1016/S0002-9440(10)63798-4

F. H. Hsue, S. S. Wu, C. W. Chen, and Y. K. , Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma, CrossRef PubMed 78 Chuang, pp.753-738, 2009.

K. Mori, L. Goff, B. Berreur, M. Riet, A. Moreau et al., Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B, The Journal of Pathology, vol.186, issue.5, pp.555-562, 2007.
DOI : 10.4049/jimmunol.164.8.3961

J. A. Lee, J. S. Jung, D. H. Kim, J. S. Lim, M. S. Kim et al., RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma, Pediatric Blood & Cancer, vol.116, issue.5, pp.738-743, 2006.
DOI : 10.1055/s-2007-993142

A. P. Armstrong, R. E. Miller, J. C. Jones, J. Zhang, E. T. Keller et al., RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes Receptor activator of NF-kappaB ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells, Prostate CrossRef PubMed Cell Res, vol.68, issue.18, pp.92-104, 2008.

S. Mikami, K. Katsube, M. Oya, M. Ishida, T. Kosaka et al., Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas, The Journal of Pathology, vol.107, issue.4, pp.530-539, 2009.
DOI : 10.1002/path.2567

M. F. Riet, A. , L. Goff, B. Battaglia, S. Paineau et al., Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer RANK expression as a prognostic and predictive marker in breast cancer Receptor activator for nuclear factor ?B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis Receptor activator of nuclear factor ?B expression is a prognostic factor in human osteosarcoma Impact of RANK signalling on survival and chemotherapy response in osteosarcoma (2012) Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr. Blood Cancer, thyroid lesions R112 CrossRef PubMed 92 Lee. and Schwitter, M. (2015) RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward, pp.46-53, 2008.

S. Amazit, L. Meduri, G. Guiochon-mantel, A. Milgrom, E. Mariette et al., RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway The Involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily, CrossRef PubMed 94 Roux Database (Oxford) 2011, bar021 PubMed 97 Galibert, pp.210-216, 1998.

M. A. Lomaga, W. C. Yeh, I. Sarosi, G. S. Duncan, C. Furlonger et al., TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling, CrossRef PubMed 98, pp.1015-1024, 1999.
DOI : 10.1101/gad.13.8.1015

URL : http://genesdev.cshlp.org/content/13/8/1015.full.pdf

B. G. Ni, J. Moore, P. A. Aggarwal, and B. B. , Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif, EMBO J. J. Biol. Chem. Z.H. FEBS Lett, vol.24, issue.443, pp.790-799, 1999.

H. Shima, N. Nakagawa, N. Yamaguchi, K. Kinosaki, M. Mochizuki et al., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Osteoprotegerin: multiple partners for multiples functions, CrossRef PubMed 103 Yasuda, pp.3597-3602, 1998.

T. A. Gonda, S. Tu, T. C. Wang, M. Padrines, S. Theoleyre et al., OPG/membranous?RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL, CrossRef PubMed 105, pp.706-715, 1998.

I. Holen, P. I. Croucher, F. C. Hamdy, C. L. Eaton, M. Duplomb et al., Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival, CrossRef PubMed 111, pp.1619-1623, 2002.

C. Pubmed-113-luo, J. Yang, Z. Ma, Y. Yue, Z. Lin et al., LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits, CrossRef PubMed 114 Styrkarsdottir, pp.539-546, 2013.

C. Pubmed-115-zhu, Y. B. Xu, L. Chen, M. Ma, H. N. Lou et al., GPR48 promotes multiple cancer cell proliferation via activation of Wnt signaling. Asian Pac, J. Cancer Prev, vol.14, pp.4775-4578, 2013.

C. Pubmed-116-liang, F. Yue, J. Wang, J. Zhang, L. Fan et al., GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway Lgr4 is a key regulator of prostate development and prostate stem cell differentiation (2013) Stat3 upregulates leucine-rich repeat-containing g protein-coupled receptor 4 expression in osteosarcoma cells The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development, Med. Oncol. Stem Cells CrossRef PubMed Z.Q. Biomed. Res. Int. Cell, vol.32, issue.103, pp.2492-2505, 2000.

C. Pubmed-120-kim, N. S. Kim, H. J. Koo, B. K. Kwon, M. C. Kim et al., Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2, Mol. Cell Biol, vol.26, pp.1002-1013, 2006.

C. Pubmed-121-gonzalez-suarez, E. Branstetter, D. Armstrong, A. Dinh, H. Blumberg et al., RANK Overexpression in Transgenic Mice with Mouse Mammary Tumor Virus Promoter-Controlled RANK Increases Proliferation and Impairs Alveolar Differentiation in the Mammary Epithelia and Disrupts Lumen Formation in Cultured Epithelial Acini, et al. (2012) RANK induces epithelial?mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis, pp.1442-1454, 2007.
DOI : 10.1128/MCB.01298-06

C. Pubmed-124-yamada, T. Tsuda, M. Takahashi, T. Totsuka, Y. Shindoh et al., RANKL Expression Specifically Observed in Vivo Promotes Epithelial Mesenchymal Transition and Tumor Progression, The American Journal of Pathology, vol.178, issue.6, pp.2845-2856, 2011.
DOI : 10.1016/j.ajpath.2011.02.003

K. Mori, L. Goff, B. Charrier, C. Battaglia, S. Heymann et al., DU145 human prostate cancer cells express functional receptor activator of NF??B: New insights in the prostate cancer bone metastasis process, Bone, vol.40, issue.4, pp.981-890, 2007.
DOI : 10.1016/j.bone.2006.11.006

X. Li, Y. Liu, B. Wu, Z. Dong, Y. Wang et al., Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis, Oncology Reports, vol.32, issue.6, pp.2605-2611, 2011.
DOI : 10.3892/or.2014.3511

C. Pubmed-129-chen, L. M. Kuo, C. H. Lai, T. Y. Lin, Y. M. Su et al., RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation, Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY), pp.933-941, 2011.
DOI : 10.2174/138161208785740225

J. Zhou, J. Fan, Q. Gao, and X. Y. Wang, RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-?B-mediated epithelial?mesenchymal transition MPA influences tumor cell proliferation, migration, and invasion induced by RANKL through PRB involving the MAPK pathway in endometrial cancer, PLoS One Oncol. Rep, vol.9, issue.33, pp.799-809, 2014.

D. Golden, E. A. Saria, and M. F. Hansen, Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling, Journal of Cellular Physiology, vol.119, issue.12, pp.2951-2960, 2015.
DOI : 10.1016/j.jaci.2007.02.011

C. Pubmed-133-beristain, A. G. Narala, S. R. , D. Grappa, M. A. Khokha et al., Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells, Journal of Cell Science, vol.125, issue.4, pp.943-955, 2012.
DOI : 10.1242/jcs.094029

S. Mikami, K. Katsube, M. Oya, M. Ishida, T. Kosaka et al., Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas, The Journal of Pathology, vol.107, issue.4, pp.530-539, 2009.
DOI : 10.1002/path.2567

C. Pubmed-135-min, J. K. Kim, Y. M. Kim, Y. M. Kim, E. C. Gho et al., Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells: concomitant increase of angiogenic responses to RANK ligand, TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells, pp.39548-39557, 2002.

C. Pubmed-137-kim, H. H. Shin, H. S. Kwak, H. J. Ahn, K. Y. Kim et al., RANKL regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties, FASEB J. Z. J. Thromb. Haemost, vol.17, issue.9, pp.2163-2165, 2003.

C. Pubmed-139-min, J. K. Cho, Y. L. Choi, J. H. Kim, Y. Kim et al., Receptor activator of nuclear factor-kB ligand increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice, Blood, vol.109, pp.1496-1502, 2007.

C. G. Mueller and E. Hess, Emerging Functions of RANKL in Lymphoid Tissues, Frontiers in Immunology, vol.3, p.261, 2012.
DOI : 10.3389/fimmu.2012.00261

C. Pubmed-141-kong, Y. Y. Yoshida, H. Sarosi, I. Tan, H. L. Timms et al., OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, vol.397, pp.315-323, 1999.

T. Akiyama, Y. Shimo, H. Yanai, J. Qin, D. Ohshima et al., The Tumor Necrosis Factor Family Receptors RANK and CD40 Cooperatively Establish the Thymic Medullary Microenvironment and Self-Tolerance, CrossRef PubMed 142, pp.423-437, 2008.
DOI : 10.1016/j.immuni.2008.06.015

URL : https://doi.org/10.1016/j.immuni.2013.09.003

T. Akiyama, M. Shinzawa, J. Qin, N. I. Akiyama, M. L. Mouchess et al., Regulations of gene expression in medullary thymic epithelial cells required for preventing the onset of autoimmune diseases Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance, CrossRef PubMed 143, pp.761-768, 2013.

C. Pubmed-145-cook, J. Hagemann, and T. , Tumour-associated macrophages and cancer, Current Opinion in Pharmacology, vol.13, issue.4, pp.595-601, 2013.
DOI : 10.1016/j.coph.2013.05.017

C. Pubmed-146-breuil, V. Schmid-antomarchi, H. Schmid-alliana, A. Rezzonico, R. Euller-ziegler et al., The receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) is a new chemotactic for human monocytes The possible interaction between receptor activator of nuclear factor kappa-B ligand expressed by extramammary paget cells and its ligand on dermal macrophages, FASEB J. J. Invest. Dermatol, vol.17, issue.135, pp.2163-2165, 2003.

T. Fujimura, Y. Kambayashi, S. Furudate, M. Asano, A. Kakizaki et al., Receptor Activator of NF-??B Ligand Promotes the Production of CCL17 from RANK+ M2 Macrophages, CrossRef PubMed 148, pp.2884-2887, 2015.
DOI : 10.1038/jid.2015.209

C. Pubmed-149-tan, W. Zhang, W. Strasner, A. Grivennikov, S. Cheng et al., Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL?RANK signalling, Nature, vol.470, pp.548-553, 2011.

C. Pubmed-150-monteiro, A. C. Leal, A. C. Gonçalves-silva, T. Mercadante, A. C. Kestelman et al., Cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer Targeting tumor-stromal interactions in bone metastasis, PLoS One Pharmacol. Ther, vol.8, issue.141, pp.222-233, 2013.

C. Pubmed-152-bekker, P. J. Holloway, D. Nakanishi, A. Arrighi, M. Leese et al., The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women, CrossRef PubMed 153 Gobin, Future Medicine Ltd 154 Bekker, pp.348-360, 2001.
DOI : 10.1359/jbmr.2001.16.2.348

G. Picarda, E. Matous, J. Amiaud, C. Charrier, F. Lamoureux et al., Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL, Journal of Bone Oncology, vol.2, issue.3, pp.95-104, 2013.
DOI : 10.1016/j.jbo.2013.04.004

C. Pubmed-156-lamoureux, F. Richard, P. Wittrant, Y. Battaglia, S. Pilet et al., Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis, RANK?RANKL and cancer 157, pp.7308-7318, 2007.

C. Pubmed-159-miller, R. E. Roudier, M. Jones, J. Armstrong, A. Canon et al., RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis, Molecular Cancer Therapeutics, vol.7, issue.7, pp.2160-2169, 2008.
DOI : 10.1158/1535-7163.MCT-08-0046

C. Pubmed-161-vanderkerken, K. De-leenheer, E. Shipman, C. Asosingh, K. Willems et al., Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics, Cancer Res. Eur. J. Cancer, vol.63, issue.53, pp.287-289, 2003.